RASAGILINE MESYLATE Drug Patent Profile
✉ Email this page to a colleague
When do Rasagiline Mesylate patents expire, and when can generic versions of Rasagiline Mesylate launch?
Rasagiline Mesylate is a drug marketed by Alkem Labs Ltd, Apotex Inc, Aurobindo Pharma Usa, Carnegie, Chartwell Rx, Indoco, Micro Labs, Orbion Pharms, Skg Pharma, and Watson Labs Inc. and is included in ten NDAs.
The generic ingredient in RASAGILINE MESYLATE is rasagiline mesylate. There are eighteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the rasagiline mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rasagiline Mesylate
A generic version of RASAGILINE MESYLATE was approved as rasagiline mesylate by ORBION PHARMS on March 15th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RASAGILINE MESYLATE?
- What are the global sales for RASAGILINE MESYLATE?
- What is Average Wholesale Price for RASAGILINE MESYLATE?
Summary for RASAGILINE MESYLATE
US Patents: | 0 |
Applicants: | 10 |
NDAs: | 10 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 113 |
Clinical Trials: | 14 |
Patent Applications: | 197 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for RASAGILINE MESYLATE |
DailyMed Link: | RASAGILINE MESYLATE at DailyMed |
![RASAGILINE MESYLATE drug patent expirations Drug patent expirations by year for RASAGILINE MESYLATE](/p/graph/s/t/RASAGILINE_MESYLATE-patent-expirations.png)
![Drug Prices for RASAGILINE MESYLATE](/p/graph/drug-price/RASAGILINE+MESYLATE.png)
Recent Clinical Trials for RASAGILINE MESYLATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Teva Pharmaceutical Industries | Phase 1 |
Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 |
Teva Pharmaceutical Industries | Phase 4 |
Pharmacology for RASAGILINE MESYLATE
Drug Class | Monoamine Oxidase Inhibitor |
Mechanism of Action | Monoamine Oxidase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for RASAGILINE MESYLATE
Paragraph IV (Patent) Challenges for RASAGILINE MESYLATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
AZILECT | Tablets | rasagiline mesylate | 0.5 mg and 1 mg | 021641 | 5 | 2010-05-17 |
US Patents and Regulatory Information for RASAGILINE MESYLATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alkem Labs Ltd | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 201889-001 | Oct 30, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Skg Pharma | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 218163-002 | Apr 9, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Carnegie | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 201942-001 | Nov 18, 2021 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Apotex Inc | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 201950-002 | Sep 12, 2013 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Indoco | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 206153-002 | Oct 4, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |